Syndax Pharmaceuticals, Inc. Operating Lease, Expense
Syndax Pharmaceuticals, Inc. (SNDX) reported Operating Lease, Expense of $900.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2026-02-26
- Syndax Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-12-31 was $82.00K.
- Syndax Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-09-30 was $122.00K.
- Syndax Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-06-30 was $130.00K.
- Syndax Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2019-03-31 was $113.00K.
- Syndax Pharmaceuticals, Inc. operating lease, expense for fiscal 2025 was $900.00K, a 18.18% decline from fiscal 2024.
- Syndax Pharmaceuticals, Inc. operating lease, expense for fiscal 2024 was $1.10M, a 48.05% increase from fiscal 2023.
- Syndax Pharmaceuticals, Inc. operating lease, expense for fiscal 2023 was $743.00K, a 68.86% increase from fiscal 2022.
- Syndax Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $440.00K, a 6.54% increase from fiscal 2021.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2025-12-31 | $900.00K 10-K · filed 2026-02-26 | |||
| 2024-12-31 | $1.10M 10-K · filed 2025-03-03 | |||
| 2023-12-31 | $743.00K 10-K · filed 2024-02-27 | |||
| 2022-12-31 | $440.00K 10-K · filed 2023-02-28 | |||
| 2021-12-31 | $413.00K 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $425.00K 10-K · filed 2021-03-12 | |||
| 2019-12-31 | $82.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | $204.00K derived: sum of 2 quarters · filed 2020-03-05 | $334.00K derived: sum of 3 quarters · filed 2020-03-05 | $447.00K 10-K · filed 2020-03-05 |
| 2019-09-30 | $122.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07 | $252.00K derived: sum of 2 quarters · filed 2019-11-07 | $365.00K 10-Q · filed 2019-11-07 | |
| 2019-06-30 | $130.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-07 | $243.00K 10-Q · filed 2019-08-07 | ||
| 2019-03-31 | $113.00K 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |